Lupus

In October, Boehringer Ingelheim’s Cyltezo was approved by the FDA as the first interchangeable biosimilar to AbbVie’s Humira.

Low disease activity and remission definitions used for adult systemic lupus erythematosus are achievable among children and can significantly reduce the risk for severe flare, according to data published in Rheumatology.

Significant knowledge and research gaps are making it difficult to provide evidence-based recommendations on induced abortion to patients with rheumatic disease, according to a review article published in Arthritis Care & Research.

The majority of patients with systemic lupus erythematosus experience persistent depression despite disease activity changes and use of medications for mood disorders, pain and lupus, according to data published in Arthritis Care & Research.

Rheumatology patients and clinicians alike express a “strong” preference for in-person visits rather than telemedicine, citing concerns over reduced assessment accuracy and increased inequality for vulnerable groups, according to data from the U.K.

A median of just 16.2% of adults with arthritis attended a self-management class in 2019, while that same year 69.3% received counseling for physical activity from their provider, according to CDC researchers.

Belimumab after rituximab reduces serum IgG anti-double-stranded DNA antibody levels and the risk for severe flare in systemic lupus erythematosus refractory to conventional therapy, according to data.

Rheumatologists who prescribe hydroxychloroquine or chloroquine should be aware of their potential cardiac toxicity, especially in high-risk patients with rheumatic disease, according to an American College of Rheumatology white paper.

The risk for hydroxychloroquine retinopathy increases with higher dosing per actual and ideal body weight, and with longer duration of use, according to data presented at ACR Convergence 2021.

A 300-mg dose of anifrolumab provided clinically meaningful benefit and was generally well-tolerated among patients with systemic lupus erythematosus, regardless of previous exposure to biologic agents, according to data presented at ACR Convergence 2021.